| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study (NCT06855706) | Roswell Park Cancer Institute | 2025-06-04 |
| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03735589) | Roswell Park Cancer Institute | 2023-12-15 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer (NCT05368506) | OHSU Knight Cancer Institute | 2023-07-30 |
| PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT05465941) | Mayo Clinic | 2022-09-14 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer (NCT05276973) | National Cancer Institute (NCI) | 2022-09-08 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer (NCT05415709) | Ohio State University Comprehensive Cancer Center | 2022-06-13 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients (NCT05047926) | Mayo Clinic | 2021-10-05 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534) | National Cancer Institute (NCI) | 2021-06-01 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (NCT04575935) | M.D. Anderson Cancer Center | 2020-08-05 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (NCT03968406) | M.D. Anderson Cancer Center | 2019-09-26 |
| Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04095364) | NRG Oncology | 2019-09-20 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery (NCT03943173) | M.D. Anderson Cancer Center | 2019-06-07 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527) | Precigen, Inc | 2019-04-30 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (NCT03508570) | M.D. Anderson Cancer Center | 2018-09-21 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |